Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Safety Woes Make Country Of Origin Labeling "Foregone Conclusion" - Execs

This article was originally published in PharmAsia News

Executive Summary

Supplement firms should not underestimate the potential for consumers' concerns about the safety of raw materials imported from China to affect their sales, industry executives said Oct. 6 at the Council for Responsible Nutrition's annual conference

You may also be interested in...



Foreign Drug Inspections Would Be Funded By Registration Fees In Draft U.S. Bill

U.S. FDA inspections of overseas drug producers would be supported by annual registration fees under a legislative "discussion draft" being circulated by House Energy and Commerce Committee Chairman John Dingell, D-Mich.

Foreign Drug Inspections Would Be Funded By Registration Fees In Draft U.S. Bill

U.S. FDA inspections of overseas drug producers would be supported by annual registration fees under a legislative "discussion draft" being circulated by House Energy and Commerce Committee Chairman John Dingell, D-Mich.

Dingell Import Safety Bill Includes User Fees To Fund Foreign Inspections

Legislation introduced by House Energy and Commerce Committee members Sept. 20 to improve food and drug import safety would authorize user fees to be directed at hiring more FDA inspectors and other officials for import analysis in the U.S. and abroad

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC065696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel